October 6, 2016 – InDex Pharmaceuticals Holding AB (publ) has met the requirements for listing on Nasdaq First North Stockholm and the marketplace has now given its formal approval to the company. First day of trading in the share is Tuesday, October 11, 2016. The share will be traded under the ticker INDEX and with the ISIN code SE0008966295.
InDex Pharmaceuticals recently completed a new share issue of SEK 250 million. Approximately 5,000 investors were allotted shares in the IPO issue.
“We are pleased to confirm that trading in InDex shares begins on First North on Tuesday. We will now focus on bringing our lead drug candidate cobitolimod through the next value increasing phase. We will initiate a phase IIb clinical study in the debilitating inflammatory bowel disease ulcerative colitis with the goal to optimise the treatment with cobitolimod”, says Peter Zerhouni, CEO of InDex Pharmaceuticals.
The listing ceremony at Nasdaq Stockholm and the initial trading of the shares will be broadcasted live, starting at 08:40 am, via the link www.investerarbrevet.se/InDex.
Redeye AB will be the company’s Certified Adviser on First North.
For more information:
Peter Zerhouni, CEO
Phone: +46 8 508 847 35
E-mail: [email protected]
Advisers
Stockholm Corporate Finance AB is the financial adviser and Setterwalls Advokatbyrå AB is the legal adviser to the company in relation to the listing.
InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The Company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis – a debilitating, chronic inflammation of the large intestine.
Cobitolimod is a new type of drug that can help patients with moderate to severe ulcerative colitis back to a normal life. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
InDex is based in Stockholm with address Tomtebodavägen 23a, 171 77 Stockholm, Sweden. The Company’s operations are mainly conducted through its subsidiary Index Pharmaceuticals AB. For more information, please visit www.indexpharma.com.
